MCID: BCK003
MIFTS: 46

Background Diabetic Retinopathy

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Background Diabetic Retinopathy

MalaCards integrated aliases for Background Diabetic Retinopathy:

Name: Background Diabetic Retinopathy 12 15
Non Proliferative Diabetic Retinopathy 12
Non-Proliferative Diabetic Retinopathy 12
Nonproliferative Diabetic Retinopathy 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13208
ICD9CM 34 362.03
NCIt 49 C35668
SNOMED-CT 67 390834004
UMLS 71 C0004606

Summaries for Background Diabetic Retinopathy

MalaCards based summary : Background Diabetic Retinopathy, also known as non proliferative diabetic retinopathy, is related to microvascular complications of diabetes 1 and severe nonproliferative diabetic retinopathy. An important gene associated with Background Diabetic Retinopathy is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are TGF-Beta Pathway and PAK Pathway. The drugs Methylcobalamin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Background Diabetic Retinopathy

Diseases related to Background Diabetic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 563)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.3 VEGFA INS ICAM1 EDN1 ANGPT2 AKR1B1
2 severe nonproliferative diabetic retinopathy 31.9 VEGFA RRBP1 PGF INS ICAM1 GADD45G
3 hypertensive retinopathy 30.6 VEGFA ALB ACE
4 retinal microaneurysm 30.3 VEGFA RRBP1 INS GADD45G AKR1B1
5 diabetic macular edema 29.4 VEGFB VEGFA PGF IL6 ICAM1 AKR1B1
6 cataract 28.9 VEGFA TNF SORD INS IL6 ICAM1
7 microvascular complications of diabetes 5 28.7 VEGFA SORD PGF KDR INS ICAM1
8 optic nerve disease 28.6 VEGFA TNF IL6 IL1B EDN1 ALB
9 vascular disease 27.9 VEGFA TNF KDR INS IL6 ICAM1
10 macular retinal edema 27.1 VEGFB VEGFA TNF PGF KDR INS
11 diabetes mellitus 26.2 VEGFA TNF SORD KDR INS IL6
12 microvascular complications of diabetes 2 10.9
13 heterophyiasis 10.5 ICAM1 ALB
14 hypertensive encephalopathy 10.5 VEGFA ALB ACE
15 hypertensive nephropathy 10.5 VEGFA ALB ACE
16 retroperitoneal hemangiopericytoma 10.4 VEGFA INS
17 kidney hypertrophy 10.4 INS ALB ACE
18 glomerular disease 10.4 ALB ACE
19 orthostatic proteinuria 10.4 ALB ACE
20 drug allergy 10.4 INS ALB ACE
21 diabetic autonomic neuropathy 10.4 INS AKR1B1 ACE
22 maturity-onset diabetes of the young, type 1 10.4 INS ALB ACE
23 epithelioid hemangioendothelioma 10.4 VEGFA PGF KDR
24 peripartum cardiomyopathy 10.4 VEGFA PGF ACE
25 severe pre-eclampsia 10.4 VEGFA PGF ALB
26 histoplasmosis pericarditis 10.4 TNF ACE
27 yemenite deaf-blind hypopigmentation syndrome 10.4
28 central retinal vein occlusion 10.4 VEGFA PGF IL6
29 blood protein disease 10.3 VEGFA IL6 ALB
30 uveoparotid fever 10.3 TNF ACE
31 diabetes mellitus, insulin-dependent, 23 10.3 TNF INS
32 subacute cutaneous lupus erythematosus 10.3 TNF ACE
33 external pathological resorption 10.3 TNF IL6
34 capillary hemangioma 10.3 VEGFA KDR ANGPT2
35 inflammatory and toxic neuropathy 10.3 TNF INS ALB
36 heart conduction disease 10.3 INS ALB ACE
37 nodular goiter 10.3 VEGFA IL6 ICAM1
38 duodenitis 10.3 TNF INS ALB
39 scorpion envenomation 10.3 TNF IL6
40 aspiration pneumonia 10.3 IL6 ALB ACE
41 intermediate coronary syndrome 10.3 INS IL6 ACE
42 idiopathic edema 10.3 INS EDN1 ACE
43 acute mountain sickness 10.3 VEGFA EDN1 ACE
44 placenta accreta 10.3 PGF KDR ANGPT2
45 fuchs' heterochromic uveitis 10.3 IL6 ACE
46 idiopathic anterior uveitis 10.3 TNF IL6
47 tricuspid valve insufficiency 10.3 EDN1 ALB ACE
48 tricuspid valve disease 10.3 EDN1 ALB ACE
49 diabetic cataract 10.2 VEGFA SORD INS AKR1B1
50 hepatorenal syndrome 10.2 EDN1 ALB ACE

Graphical network of the top 20 diseases related to Background Diabetic Retinopathy:



Diseases related to Background Diabetic Retinopathy

Symptoms & Phenotypes for Background Diabetic Retinopathy

MGI Mouse Phenotypes related to Background Diabetic Retinopathy:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ACE AGER AKR1B1 ALB ANGPT2 EDN1
2 cardiovascular system MP:0005385 10.32 ACE AGER ALB ANGPT2 EDN1 ICAM1
3 growth/size/body region MP:0005378 10.25 ACE AGER AKR1B1 EDN1 ICAM1 IL1B
4 immune system MP:0005387 10.18 ACE AGER ALB ANGPT2 GADD45G ICAM1
5 digestive/alimentary MP:0005381 10.06 ALB ANGPT2 EDN1 ICAM1 IL6 INS
6 adipose tissue MP:0005375 10.04 ACE GADD45G IL6 INS PGF TNF
7 integument MP:0010771 10.02 AGER ANGPT2 ICAM1 IL1B IL6 INS
8 muscle MP:0005369 9.91 AGER ALB EDN1 ICAM1 IL6 INS
9 neoplasm MP:0002006 9.76 ACE ALB ICAM1 IL1B IL6 PGF
10 renal/urinary system MP:0005367 9.61 ACE AGER AKR1B1 ALB EDN1 GADD45G
11 vision/eye MP:0005391 9.36 AKR1B1 ANGPT2 ICAM1 IL6 INS KDR

Drugs & Therapeutics for Background Diabetic Retinopathy

Drugs for Background Diabetic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Bevacizumab Approved, Investigational Phase 4 216974-75-3
4
Ranibizumab Approved Phase 4 347396-82-1 459903
5 Grape Approved Phase 4
6
tannic acid Approved Phase 4 1401-55-4
7
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
14
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
15
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
16
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
17 Vitamin B 6 Phase 4
18 Hematinics Phase 4
19 Angiogenesis Inhibitors Phase 4
20 Antineoplastic Agents, Immunological Phase 4
21 Anesthetics Phase 4
22 Hormones Phase 4
23 Hemostatics Phase 4
24 Coagulants Phase 4
25 Calcium, Dietary Phase 4
26 Calcium Dobesilate Phase 4
27 Gastrointestinal Agents Phase 4
28 Methylprednisolone Acetate Phase 4
29 Hormone Antagonists Phase 4
30 glucocorticoids Phase 4
31 Antineoplastic Agents, Hormonal Phase 4
32 Neuroprotective Agents Phase 4
33 Antiemetics Phase 4
34 Anti-Inflammatory Agents Phase 4
35 Protective Agents Phase 4
36 Ophthalmic Solutions Phase 4
37 BB 1101 Phase 4
38
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
39
Calcium Nutraceutical Phase 4 7440-70-2 271
40
Nepafenac Approved, Investigational Phase 3 78281-72-8 151075
41
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
42
Copper Approved, Investigational Phase 3 7440-50-8 27099
43
Fenofibrate Approved Phase 3 49562-28-9 3339
44
Zinc oxide Approved Phase 3 1314-13-2
45
Magnesium oxide Approved Phase 3 1309-48-4 14792
46
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
47
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
48
Insulin aspart Approved Phase 2, Phase 3 116094-23-6 16132418
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
50
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
2 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
3 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
4 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
5 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
6 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
7 Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness Completed NCT01504724 Phase 4 bevacizumab
8 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo
9 Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial Active, not recruiting NCT02874313 Phase 4 Pharmacological treatment
10 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Not yet recruiting NCT04283162 Phase 4 Calcium Dobesilate
11 DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery Not yet recruiting NCT04362241 Phase 4 Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
12 A Randomized, Double Blind, Multi-Center Study of Compound Danshen Dripping Pills in Patients With Diabetic Retinopathy (Syndrome Of Qi-Stagnation and Blood Stasis) Unknown status NCT02388984 Phase 3 Compound danshen dripping pills;Placebo
13 Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery Completed NCT01872611 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
14 Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery Completed NCT01853072 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
15 Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy. Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
16 A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy Completed NCT02718326 Phase 3 Intravitreal aflibercept injection [IAI];Sham
17 A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally. Recruiting NCT01320345 Phase 3 Fenofibrate;Inert lactose placebo
18 Effect of Prolonged Combined Antioxidant Therapy Intake on Oxidative Stress and Mitochondrial Dysfunction Markers in Patients With Diabetic Retinopathy Recruiting NCT03702374 Phase 3 Combined antioxidant therapy
19 Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk Active, not recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
20 An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR) Terminated NCT00248157 Phase 3 Octreotide acetate in microspheres
21 An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR) Terminated NCT00248131 Phase 3 Octreotide acetate in microspheres
22 PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD) Terminated NCT03345901 Phase 3 Pemafibrate;Placebo
23 Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy Terminated NCT00287651 Phase 2, Phase 3
24 A Randomized, Double-masked, Multicenter, Placebo Controlled Study of Keluo Xin Capsule on Efficacy and Safety in Patients With Diabetic Retinopathy Unknown status NCT03258242 Phase 2 Keluo Xin capsule;Placebo oral capsule
25 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
26 Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy Completed NCT03197870 Phase 2 AKB-9778;Placebo
27 Protocol PVD-202: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD in Non-Proliferative Diabetic Retinopathy Completed NCT02435862 Phase 2 1.0mg Luminate®;2.0mg Luminate®;3.0mg Luminate®
28 An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy Completed NCT00198471 Phase 2 Vitrase
29 A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Non-proliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study) Completed NCT03238963 Phase 2 BI 1467335;Placebo
30 A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR) Completed NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
31 Efficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study Completed NCT02062034 Phase 2 Ubiquinone;Combined antioxidant therapy;Placebo
32 A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE Completed NCT01552408 Phase 1, Phase 2 0.3 mg ranibizumab
33 Proof-of-Concept 2 (POC2): Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Progression in Patients With Mild to Moderate Non-Proliferative Diabetic Retinopathy Completed NCT00917553 Phase 2 doxycycline monohydrate;Placebo
34 Evaluation of Effect of Doxycycline Verses Placebo on Diabetic Retinopathy Progression and Retinal Function in Patients With Severe Non-proliferative or Mild or Moderate (Non-high-risk) Proliferative Diabetic Retinopathy Completed NCT00511875 Phase 2 doxycycline monohydrate;placebo
35 Lucentis in the Treatment of Macular Edema - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab Versus Focal Laser Treatment in Subjects With Diabetic Macular Edema Completed NCT00387582 Phase 2 Ranibizumab (Lucentis)
36 A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy Recruiting NCT04265261 Phase 2 Placebo;RG7774
37 Effect of Combined Antioxidant Therapy on the Levels of Oxidative Stress Markers in Aqueous and Vitreous Humor of Patients With Proliferative Diabetic Retinopathy Recruiting NCT04071977 Phase 2 Combined antioxidant therapy
38 Randomized, Parallel Controlled, Clinical-trial on 532nm Laser Partially Subthreshold Panretinal Photocoagulation With PASCAL Endpoint Management Function for Severe Non-proliferative Diabetic Retinopathy(NPDR) Unknown status NCT01759121
39 Early Laser Treatment for Diabetic Eye Disease in China: The PEARL Pilot Randomized Trial Unknown status NCT02956759
40 OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy Unknown status NCT02353923
41 Diabetic Macular Edema and Diabetic Retinopathy Identification by Screening (Telemed) With Verified Automated Retinal Photography Unknown status NCT01790945
42 Phenotypes of Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Patients Identified by Optical Coherence Tomography, Colour Fundus Photography, Fluorescein Leakage and Multifocal Electrophysiology (DIAMARKER Project: Genetic Susceptibility for Multi-systemic Complications in Diabetes Type-2: New Biomarkers for Diagnostic and Therapeutic Monitoring). Completed NCT01440660
43 Identifying Progression of Retinal Disease in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures Completed NCT01145599
44 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Completed NCT02521116
45 RETeval Calibration / Validation Study - Diabetic Retinopathy Completed NCT01950663
46 Analysis of Soluble Mediators of Inflammation and Angiogenesis in the Vitreous of Patients With Diabetic Retinopathy Treated With Curcumin/Homotaurine/Vit. D3 Completed NCT04378972
47 Biomarkers of Diabetic Retinopathy Progression. Completed NCT01607190
48 Corneal Changes in Diabetics After Phacoemulsification Completed NCT02548273
49 Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Completed NCT00763802
50 Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography Completed NCT01220804

Search NIH Clinical Center for Background Diabetic Retinopathy

Genetic Tests for Background Diabetic Retinopathy

Anatomical Context for Background Diabetic Retinopathy

MalaCards organs/tissues related to Background Diabetic Retinopathy:

40
Eye, Endothelial, Retina, Brain, Testes, B Cells, Thyroid

Publications for Background Diabetic Retinopathy

Articles related to Background Diabetic Retinopathy:

(show top 50) (show all 637)
# Title Authors PMID Year
1
Serum myostatin levels are positively associated with diabetic retinopathy in individuals with type 2 diabetes mellitus. 61
32354624 2020
2
Statin reduces the incidence of diabetic retinopathy and its need for intervention: A systematic review and meta-analysis. 61
32530705 2020
3
Screening for diabetic retinopathy in diabetic patients with a mydriasis-free, full-field flicker electroretinogram recording device. 61
31720980 2020
4
Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c. 61
32494901 2020
5
Comparison of inflammatory cytokines levels in the aqueous humor with diabetic retinopathy. 61
32556740 2020
6
Vascular resistance of carotid and vertebral arteries is associated with retinal microcirculation measured by laser speckle flowgraphy in patients with type 2 diabetes mellitus. 61
32502691 2020
7
Quantification of diabetic macular ischemia using novel three-dimensional optical coherence tomography angiography metrics. 61
32526048 2020
8
Elevation in Circulating Soluble CD40 Ligand Concentrations in Type 2 Diabetic Retinopathy and Association with its Severity. 61
30149416 2020
9
Autoimmune Thyroid Disease is Associated with a Lower Prevalence of Diabetic Retinopathy in Patients with Type 1 Diabetic Mellitus. 61
32466561 2020
10
Diabetic retinopathy progression 6 months post-cataract surgery with intravitreous bevacizumab vs triamcinolone: A secondary analysis of the DiMECAT trial. 61
32356581 2020
11
Vascular changes precede tomographic changes in diabetic eyes without retinopathy and improve artificial intelligence diagnostics. 61
32392370 2020
12
Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy. 61
31586167 2020
13
Non-Proliferative Diabetic Retinopathy Is Characterized by Nonuniform Alterations of Peripapillary Capillary Networks. 61
32340031 2020
14
Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study. 61
32241206 2020
15
Retinal vasculature-function correlation in non-proliferative diabetic retinopathy. 61
31552568 2020
16
Multiple Bioinformatics Analyses of Integrated Gene Expression Profiling Data and Verification of Hub Genes Associated with Diabetic Retinopathy. 61
32294661 2020
17
Effects of diabetes duration and HgA1C level on corneal endothelial morphology. 61
32321301 2020
18
Automated Quantification of Hyperreflective Foci in SD-OCT With Diabetic Retinopathy. 61
31329137 2020
19
Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis. 61
32298984 2020
20
Hydrogen sulfide serves as a biomarker in the anterior segment of patients with diabetic retinopathy. 61
31894458 2020
21
Prevalence of Diabetic Retinopathy in Type 1 and Type 2 Diabetes Mellitus Patients in North-East Poland. 61
32268561 2020
22
Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus. 61
32132382 2020
23
Novel biomarker of sphericity and cylindricity indices in volume-rendering optical coherence tomography angiography in normal and diabetic eyes: a preliminary study. 61
31907642 2020
24
Citicoline and Vitamin B12 Eye Drops in Type 1 Diabetes: Results of a 3-year Pilot Study Evaluating Morpho-Functional Retinal Changes. 61
32180131 2020
25
Evaluation of choroidal thickness, macular thickness, and aqueous flare after cataract surgery in patients with and without diabetes: a prospective randomized study. 61
32169068 2020
26
Expression of Neovascular Associated Factors PEDF and αB-crystallin in Human Lens Epithelial Cells. 61
32208037 2020
27
The effect of diabetes mellitus on corneal endothelial cells and central corneal thickness: A case-control study. 61
32172250 2020
28
Widefield optical coherence tomography angiography for early detection and objective evaluation of proliferative diabetic retinopathy. 61
32193221 2020
29
Traditional chinese medicine for diabetic retinopathy: A systematic review and meta-analysis. 61
32049817 2020
30
The effects of hyperbaric oxygen therapy on diabetic retinopathy: A preliminary study. 61
31831276 2020
31
Discordant vascular parameter measurements in diabetic and non-diabetic eyes detected by different optical coherence tomography angiography devices. 61
32544179 2020
32
Association of candidate gene polymorphisms with diabetic retinopathy in Chinese patients with type 2 diabetes. 61
32090041 2020
33
Correlations Between Optical Coherence Tomography Angiography Parameters and the Visual Acuity in Patients with Diabetic Retinopathy. 61
32425497 2020
34
Pupillary light responses in type 1 and type 2 diabetics with and without retinopathy. 61
31943805 2020
35
Do Genomic Factors Play a Role in Diabetic Retinopathy? 61
31947513 2020
36
Albumin excretion rate among patients with diabetic retinopathy. 61
32509246 2020
37
Analysis of quantitative correlations between microaneurysm, ischaemic index and new vessels in ultrawide-field fluorescein angiography images using automated software. 61
30872285 2019
38
Barriers for Adherence to Diabetic Retinopathy Screening among Saudi Adults. 61
31897356 2019
39
[Comparison Between Automated and Manual Measurement of Foveal Avascular Zone Retinopathy in Optical Coherence Tomography]. 61
31671461 2019
40
Serum erythropoietin concentration and its correlation with stage of diabetic retinopathy. 61
31727007 2019
41
Correlations of the severity of diabetic retinopathy with EPO, Caspase-3 expression and oxidative stress. 61
31799636 2019
42
Deep learning based retinal OCT segmentation. 61
31561100 2019
43
The effect of single dose adjunctive dexamethasone implant on diabetic macular edema in patients on anti-vascular endothelial growth factor treatment: 1 year follow-up from a real-life practice. 61
31196662 2019
44
Association of central arterial stiffness with the presence and severity of diabetic retinopathy in Asians with type 2 diabetes. 61
31046450 2019
45
Hyperglycemia potentiates the effect of ionic calcium in photoreceptor ellipsoid zone disruption in diabetic retinopathy. 61
30628026 2019
46
Incidence of sight-threatening diabetic retinopathy in people with Type 2 diabetes mellitus and numbers needed to screen: a systematic review. 61
30677170 2019
47
Polymorphisms in Sorbitol-Aldose Reductase (Polyol) Pathway Genes and Their Influence on Risk of Diabetic Retinopathy Among Han Chinese. 61
31539366 2019
48
The effect of hyperbaric oxygen therapy on retinal thickness and progression of retinopathy in patients with Type 2 diabetes: a prospective cohort study. 61
31010336 2019
49
Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? 61
31206973 2019
50
Diabetes induces IL-17A-Act1-FADD-dependent retinal endothelial cell death and capillary degeneration. 61
31239234 2019

Variations for Background Diabetic Retinopathy

Expression for Background Diabetic Retinopathy

Search GEO for disease gene expression data for Background Diabetic Retinopathy.

Pathways for Background Diabetic Retinopathy

Pathways related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 VEGFB VEGFA TNF PGF KDR INS
2
Show member pathways
13.3 VEGFB TNF PGF KDR IL6 IL1B
3
Show member pathways
13.05 VEGFB PGF KDR INS IL6 ACE
4
Show member pathways
12.94 VEGFA TNF IL6 IL1B ICAM1 ANGPT2
5
Show member pathways
12.91 VEGFB VEGFA TNF PGF KDR INS
6 12.85 VEGFB VEGFA PGF IL6 GADD45G EDN1
7
Show member pathways
12.85 VEGFA TNF INS IL6 IL1B ICAM1
8
Show member pathways
12.81 TNF IL6 IL1B ICAM1 GADD45G
9
Show member pathways
12.74 VEGFB VEGFA PGF KDR INS ANGPT2
10
Show member pathways
12.7 VEGFB TNF PGF KDR IL6 IL1B
11 12.28 VEGFB VEGFA TNF PGF KDR INS
12
Show member pathways
12.27 VEGFB TNF PGF KDR IL6 IL1B
13
Show member pathways
12.26 TNF IL6 EDN1 ACE
14
Show member pathways
12.21 TNF INS IL6 IL1B ICAM1 ALB
15 12.19 VEGFA TNF IL6 IL1B
16 12.05 VEGFA KDR INS IL6 ALB
17 12.02 TNF IL6 IL1B ICAM1
18 11.97 VEGFA TNF IL6 IL1B ICAM1
19 11.94 TNF IL1B ICAM1 GADD45G
20 11.94 TNF IL6 IL1B ICAM1 EDN1
21
Show member pathways
11.88 VEGFB VEGFA PGF KDR
22 11.88 VEGFA TNF KDR IL1B ICAM1 EDN1
23 11.87 VEGFA INS IL6 EDN1 ANGPT2
24 11.76 TNF IL6 IL1B
25 11.74 TNF IL6 IL1B
26 11.73 VEGFA TNF IL6 IL1B ICAM1
27 11.68 TNF IL6 IL1B EDN1
28 11.62 TNF IL6 IL1B
29 11.59 VEGFB VEGFA EDN1
30 11.56 TNF IL6 IL1B ICAM1
31 11.54 VEGFA INS IL6
32 11.54 TNF IL6 IL1B ICAM1
33 11.52 TNF IL6 ICAM1 AGER
34
Show member pathways
11.52 VEGFA TNF IL6 IL1B ICAM1
35 11.5 TNF IL6 IL1B
36 11.48 VEGFB VEGFA KDR
37
Show member pathways
11.46 VEGFA KDR INS
38 11.4 VEGFA EDN1 ANGPT2
39 11.37 TNF IL6 IL1B
40 11.33 TNF IL6 IL1B
41 11.33 TNF IL6 IL1B ICAM1
42 11.31 TNF IL6 IL1B
43 11.27 TNF IL6 IL1B
44 11.23 VEGFB VEGFA TNF IL6 IL1B ICAM1
45 11.01 VEGFB TNF PGF KDR IL6 IL1B
46 10.98 TNF IL1B ICAM1
47
Show member pathways
10.66 VEGFB VEGFA PGF KDR
48 10.65 VEGFB VEGFA

GO Terms for Background Diabetic Retinopathy

Cellular components related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 VEGFB VEGFA TNF PGF KDR INS
2 extracellular space GO:0005615 9.47 VEGFB VEGFA TNF SORD PGF INS
3 platelet alpha granule lumen GO:0031093 9.33 VEGFB VEGFA ALB

Biological processes related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.13 VEGFA TNF INS IL6 IL1B
2 response to drug GO:0042493 10.07 VEGFB SORD PGF ICAM1 EDN1
3 negative regulation of gene expression GO:0010629 10.07 VEGFA TNF KDR EDN1 ACE
4 positive regulation of cell proliferation GO:0008284 10.07 VEGFA PGF KDR INS IL6 IL1B
5 cytokine-mediated signaling pathway GO:0019221 10.06 VEGFA TNF IL6 IL1B ICAM1
6 angiogenesis GO:0001525 10.04 VEGFB VEGFA PGF KDR ANGPT2
7 positive regulation of cell migration GO:0030335 10.04 VEGFA KDR INS IL1B EDN1
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.02 TNF KDR ICAM1 AGER
9 leukocyte migration GO:0050900 10.01 TNF IL1B ICAM1 ANGPT2
10 cellular response to lipopolysaccharide GO:0071222 10 TNF IL6 IL1B ICAM1
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.96 TNF IL6 IL1B EDN1
12 positive regulation of JNK cascade GO:0046330 9.92 TNF IL1B GADD45G AGER
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 VEGFA TNF IL6
14 positive regulation of endothelial cell proliferation GO:0001938 9.9 VEGFB VEGFA PGF KDR
15 positive regulation of MAP kinase activity GO:0043406 9.89 VEGFA TNF EDN1
16 glucose metabolic process GO:0006006 9.89 TNF SORD INS
17 positive regulation of endothelial cell migration GO:0010595 9.88 VEGFA KDR EDN1
18 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IL1B
19 positive chemotaxis GO:0050918 9.87 VEGFB VEGFA PGF
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TNF IL1B EDN1 AGER
21 positive regulation of JUN kinase activity GO:0043507 9.86 TNF EDN1 AGER
22 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.86 VEGFB VEGFA PGF KDR
23 protein kinase B signaling GO:0043491 9.85 TNF KDR IL1B
24 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF INS IL6 IL1B ICAM1 AGER
25 branching involved in blood vessel morphogenesis GO:0001569 9.84 VEGFA KDR EDN1
26 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 TNF IL6 EDN1 AKR1B1
27 positive regulation of JAK-STAT cascade GO:0046427 9.83 TNF IL6 AKR1B1
28 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
29 positive regulation of mitotic nuclear division GO:0045840 9.82 INS IL1B EDN1
30 positive regulation of cell division GO:0051781 9.8 VEGFB VEGFA PGF IL1B
31 positive regulation of angiogenesis GO:0045766 9.8 VEGFB VEGFA PGF KDR IL1B ANGPT2
32 positive regulation of glial cell proliferation GO:0060252 9.79 TNF IL6 IL1B
33 negative regulation of lipid catabolic process GO:0050995 9.79 TNF INS IL1B
34 astrocyte activation GO:0048143 9.78 TNF IL1B AGER
35 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 TNF IL1B ICAM1 EDN1
36 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.77 TNF IL1B AGER
37 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.76 TNF IL1B AGER
38 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.75 TNF IL6 ICAM1
39 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
40 sprouting angiogenesis GO:0002040 9.73 VEGFB VEGFA PGF KDR
41 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.72 TNF AGER
42 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
43 vascular wound healing GO:0061042 9.72 VEGFA KDR
44 neutrophil mediated immunity GO:0002446 9.72 IL6 ACE
45 positive regulation of chemokine biosynthetic process GO:0045080 9.72 TNF IL1B AGER
46 positive regulation of prostaglandin secretion GO:0032308 9.71 IL1B EDN1
47 positive regulation of p38MAPK cascade GO:1900745 9.71 VEGFA IL1B GADD45G AGER
48 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.7 VEGFA KDR
49 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.69 VEGFA KDR
50 positive regulation of fever generation GO:0031622 9.69 TNF IL1B

Molecular functions related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.67 VEGFB VEGFA PGF IL6
2 identical protein binding GO:0042802 9.61 VEGFB VEGFA TNF SORD PGF KDR
3 cytokine activity GO:0005125 9.55 VEGFA TNF IL6 IL1B EDN1
4 chemoattractant activity GO:0042056 9.5 VEGFB VEGFA PGF
5 vascular endothelial growth factor receptor 1 binding GO:0043183 9.26 VEGFB VEGFA
6 vascular endothelial growth factor receptor binding GO:0005172 8.8 VEGFB VEGFA PGF

Sources for Background Diabetic Retinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....